


10. Use of a therapeutically effective amount of a compound according to any one of claims 1-9 in the manufacture of a medicament for the prevention or treatment of an FXR-mediated disease or condition in a mammal wherein the medicament is to be administered to the mammal suffering from the FXR-mediated disease or condition.

11. The use according to claim 10, wherein the FXR-mediated disease or condition is selected from the group consisting of chronic liver disease, gastrointestinal disease, renal disease, cardiovascular disease, and metabolic disease.

12. The use according to claim 11, wherein the chronic liver disease is selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), drug induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune hepatitis, chronic viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver transplant associated graft versus host disease, living donor transplant liver regeneration, congenital hepatic fibrosis, choledocholithiasis, granulomatous liver disease, intra- or extrahepatic malignancy, Sjogren's syndrome, Sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, and alpha 1-antitrypsin deficiency.

13. The use according to claim 11, wherein the renal disease is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS),

hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, and polycystic kidney disease.

14. The use according to claim 11, wherein the cardiovascular disease is selected from the group consisting of atherosclerosis, arteriosclerosis, dyslipidemia, hypercholesterolemia, and hypertriglyceridemia.

15. The use according to claim 11, wherein the metabolic disease is selected from the group consisting of insulin resistance, Type I and Type II diabetes, and obesity.

16. Use of a therapeutically effective amount of a compound according to any one of claims 1-9 in the manufacture of a medicament for the prevention or treatment of an TGR5-mediated disease or condition in a mammal wherein the medicament is to be administered to the mammal suffering from the TGR5-mediated disease or condition.

17. A pharmaceutical composition comprising a compound according to any one of claims 1-9 and a pharmaceutically acceptable carrier.

18. Use of a compound as defined in any one of claims 1-9 in the manufacture of a medicament for the prevention or treatment of FXR-mediated or TGR5-mediated diseases or conditions.